On 28 June 2019, orphan designation EU/3/19/2174 was granted by the European Commission to TMC Pharma (EU) Limited, Ireland, for rasagiline for the treatment of Duchenne muscular dystrophy.
|Disease / condition||
Treatment of Duchenne muscular dystrophy
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: